Michael J, Bhutani M, Cole CE. Multiple Myeloma for Primary Care Providers: A Practical Review to Facilitate Early Diagnosis in Diverse Populations. I'm J Med. 2023;136:33–41.
Google Scholar
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al Diagnosis and management of multiple myeloma: a review. jam. 2022;327:464–77.
Google Scholar
Osio EM, Perrault A, Borries P, San Miguel JF, Blau IW, Carlin L, et al. Efficacy and safety of isacuximab in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for or have no immediate intention of autologous stem cell transplantation. leukemia. 2023;37:1521–9.
Google Scholar
Kaiser MF, Hall A, Walker K, Sherborn A, de Choute RM, Newnham N, et al. Induction and long-term consolidation of daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in very high-risk multiple myeloma improve outcomes. J.C.O. 2023;41:3945–55.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene viclucel for relapsed/refractory multiple myeloma: Real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087–97.
Google Scholar
Singh S, Sharma R, Singh J, Jain K, Paul D. Autologous stem cell transplantation for multiple myeloma in the new drug era: a systematic review of Indian data and implications for resource-constrained settings. J Cancer Institute. 2023;19:S12–19.
Google Scholar
Jantunen E, Partanen A, Turunen A, Varmavuo V, Silvennoinen R. Mobilization strategies for myeloma patients for autologous hematopoietic cell transplantation. Hemother, a blood transfusion doctor. 2023;50:438–47.
Google Scholar
BW, Harrison SJ, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in myeloma patients receiving current treatments. Eur J Hematol. 2017;98:149–53.
Google Scholar
Waszczuk-Gajda A, Penack O, Sbianchi G, Koster L, Blaise D, Reményi P, et al. Complications of autologous stem cell transplantation in multiple myeloma: Results from the CALM study. J Clinical Medicine. 2022;11:3541.
Google Scholar
Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, et al. Prognostic factors for mortality in +100 day survivors after allogeneic hematopoietic cell transplantation. Bio blood bone marrow transplant. 2018;24:1029–34.
Google Scholar
Radivojevic T, Dean RM, Shaw BE, Blazauskas R, Tekka HR, Molenaar RJ, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after autologous transplantation of lymphoma and plasma cell myeloma. Leuk Inst 2018;74:130–6.
Google Scholar
Taylor PR, Jackson GH, Leonard AL, Hamilton PJ, Proctor SJ. Low incidence of myelodysplastic syndromes after transplantation using autologous non-cryopreserved bone marrow. leukemia. 1997;11:1650–3.
Google Scholar
Pedersen-Bjargaard J, Andersen MK, Christiansen DH. Treatment-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. blood. 2000;95:3273–9.
Google Scholar
Kallen ME, Koka R, Singh ZN, Ning Y, Kocoglu MH, Badros AZ, et al. Treatment-related B-lymphoblastic leukemia after multiple myeloma. Leuk Res Rep. 2022;18:100358.
Google Scholar
Yarnis FF, Greenbaum U, Pasvolski O, Milton DR, Kanagal-Shamanna R, Ramdial J, et al. Characteristics and outcomes of multiple myeloma patients who developed treatment-related acute myeloid leukemia and myelodysplastic syndrome after autologous cell transplantation. Transpl cell sir. 2024;30:205.e1–205.e12.
Google Scholar
Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, et al. Characteristics and outcomes of treatment-related myeloid neoplasms after autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11:63.
Google Scholar
Arbor DA, Orazi A, Hassajian R, Thiele J, Borowitz MJ, Le Beau MM, et al. 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. blood. 2016;127:2391–405.
Google Scholar
Mahindra A, Raval G, Mehta P, Blazauskas R, Zhang MJ, Zhong X, et al. New cancer after autologous transplantation of multiple myeloma. Bio blood bone marrow transplant. 2015;21:738–45.
Google Scholar
Richardson PG, Jacobus SJ, Weller EA, Hasson H, Ronial S, Raje NS, et al. Triplet therapy, transplant, and maintenance until myeloma progresses. N. Engl J Med. 2022;387:132–47.
Google Scholar
Govindarajan R, Jagannath S, Frick JT, Bethore DH, Sawyer J, Barlogi B, et al. Prior standard treatment may be a contributing factor to MDS after autologous transplantation for multiple myeloma. Br J Hematol. 1996;95:349–53.
Google Scholar
Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of myeloid neoplasms associated with TP53 mutation therapy. blood. 2022;140:1753–63.
Google Scholar
McCarthy PL, Ouser K, Hoffmeister CC, Hurd DD, Hasson H, Richardson PG, et al. Lenalidomide after stem cell transplantation for multiple myeloma. N. Engl J Med. 2012;366:1770–81.
Google Scholar
Attar M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Maintenance of lenalidomide after stem cell transplantation for multiple myeloma. N. Engl J Med. 2012;366:1782–91.
Google Scholar
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.
Google Scholar
Elsallab, Ellithi M, Lunning MA M, D'Angelo, Ma C, Perales MA J, et al. Second primary malignancy after commercially available CAR T-cell therapy: Analysis of the FDA Adverse Event Reporting System. blood. 2024;143:2099–105.
Google Scholar
Ghirardi G, Fraietta JA, Gerson JN, Van Dearin VM, Morissette JJD, Caponetti GC, et al. Risk of T-cell lymphoma and second primary malignancies after commercially available CAR T-cell therapy. Nat Med. 2024;30:984–9.
Google Scholar
